Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 77

The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

Liu, Zherui, Zhu, Yun, Xie, Huan, Zou, Zhengsheng·2023·Frontiers in Pharmacology
DOI 10.3389/fphar.2022.1077468PMC PMC9868416
Open this paper in CoChat — free account

Abstract

In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade. However, expanded indication and increased use of Immune checkpoint inhibitors have resulted in increased reports of toxicity called immune-related adverse events (irAEs). Due to the unique immunological characteristics of the liver, a hepatic immune-related adverse events has also been reported, which is usually termed Immune-mediated hepatitis (IMH). So far, it is generally considered that the mechanism of IMH induced by Immune checkpoint inhibitors is mainly the overactivation of T cells. It has been reported that the incidence of IMH ranges from 1% to 15%. Because of the lack of specific markers, a diagnosis of exclusion of IMH is critical. Although most IMH is mild and recoverable, several death cases have been reported, which has been increasingly concerned. This review summarizes the current understanding of the pathophysiology, epidemiology, diagnosis, management and prognosis of IMH caused by Immune checkpoint inhibitors. It also discusses the controversial issues in IMH, such as the role of liver biopsy, grading criteria, risk factors, rational treatment strategies with steroids, and the timing of Immune checkpoint inhibitors rechallenging, which may provide helpful information for IMH in future clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2022.1077468

Cites

119 of 119 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Mechanisms of T cells activation and immune-mediated hepatitis caused by ICIs. (A) Blockade of CTLA-4 activates T cells at the priming phase. (B) Further anti-tumor effect induced by the blockade of PD-1 and PD-L1 occurs in the effector phase. Once liver self-tolerance impairs, immune cells such as (C) Th cells, (D) Monocytes, (E) Treg cells, and (F) cytotoxic T cells will be involved in the pathophysiological process of immune-mediated hepatitis.
FIGURE 1 Mechanisms of T cells activation and immune-mediated hepatitis caused by ICIs. (A) Blockade of CTLA-4 activates T cells at the priming phase. (B) Further anti-tumor effect induced by the blockade of PD-1 and PD-L1 occurs in the effector phase. Once liver self-tolerance impairs, immune cells such as (C) Th cells, (D) Monocytes, (E) Treg cells, and (F) cytotoxic T cells will be involved in the pathophysiological process of immune-mediated hepatitis.CC BY · PubMed Central
FIGURE 2 Management for immune-mediated hepatitis caused by immune checkpoint inhibitors. LFT, liver function test; ICI, immune checkpoint inhibitor; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBil, total bilirubin; ULN, upper limit of normal; BLV, baseline value; MMF, mycophenolate mofetil; UDCA, ursodeoxycholic acid; ATG, antithymocyte globulin; AZA, azathioprine.
FIGURE 2 Management for immune-mediated hepatitis caused by immune checkpoint inhibitors. LFT, liver function test; ICI, immune checkpoint inhibitor; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBil, total bilirubin; ULN, upper limit of normal; BLV, baseline value; MMF, mycophenolate mofetil; UDCA, ursodeoxycholic acid; ATG, antithymocyte globulin; AZA, azathioprine.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 2017, Common terminology criteria for adverse events version 5.0

Cited by

See all 77

Metadata

Authors
Liu, Z., Zhu, Y., Xie, H., & Zou, Z.
Venue
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Published
2023-01-09
Volume
13
ISSN
1663-9812
DOI
10.3389/fphar.2022.1077468
PMC
PMC9868416
Cited by
77
References
119
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
National Natural Science Foundation of China (81670527)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.